Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein
- PMID: 12192248
- DOI: 10.1097/00002281-200209000-00007
Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein
Abstract
B lymphocyte stimulator (BLyS) protein is among the novel tumor necrosis factor (TNF) ligands and receptor superfamily members recently described. BLyS protein can promote B cell survival, expansion, and differentiation both and. Constitutive overexpression of BLyS protein can result in systemic lupus erythematosus (SLE)-like disease in mice, and circulating levels of BLyS protein are elevated in a subset of human SLE patients. Treatment of SLE mice with a BLyS protein antagonist ameliorates disease progression and enhances survival. By inference, BLyS protein may also play an important contributory role in pathogenesis and/or propagation of human SLE and becomes a legitimate candidate target for antagonist biologic agents.
Similar articles
-
Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.Arthritis Rheum. 2005 Dec;52(12):3943-54. doi: 10.1002/art.21489. Arthritis Rheum. 2005. PMID: 16320342
-
BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists.Curr Dir Autoimmun. 2005;8:289-304. doi: 10.1159/000082108. Curr Dir Autoimmun. 2005. PMID: 15564726 Review.
-
SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder.Arthritis Res Ther. 2003;5(3):136-8. doi: 10.1186/ar755. Epub 2003 Mar 27. Arthritis Res Ther. 2003. PMID: 12723979 Free PMC article.
-
B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases.Curr Rheumatol Rep. 2002 Aug;4(4):345-50. doi: 10.1007/s11926-002-0044-7. Curr Rheumatol Rep. 2002. PMID: 12126587 Review.
-
A therapeutic role for BLyS antagonists.Lupus. 2004;13(5):317-22. doi: 10.1191/0961203304lu1019oa. Lupus. 2004. PMID: 15230285 Review.
Cited by
-
Pharmacotherapy of lupus nephritis in children: a recommended treatment approach.Drugs. 2006;66(9):1191-207. doi: 10.2165/00003495-200666090-00003. Drugs. 2006. PMID: 16827597 Review.
-
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.Blood. 2004 Apr 15;103(8):3148-57. doi: 10.1182/blood-2003-06-1984. Epub 2003 Dec 4. Blood. 2004. PMID: 15070697 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous